{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:05:58Z","timestamp":1771776358656,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2024QH107"],"award-info":[{"award-number":["ZR2024QH107"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Development Plan for Youth Innovation Team in Higher School of Shandong Province","award":["2022KJ266"],"award-info":[{"award-number":["2022KJ266"]}]},{"name":"Weifang Science and Technology Development Plan Project","award":["2023GX021"],"award-info":[{"award-number":["2023GX021"]}]},{"name":"Weifang Science and Technology Development Plan Project for Medicine","award":["2023YX035"],"award-info":[{"award-number":["2023YX035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11259-7","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:25:14Z","timestamp":1750587914000},"page":"1217-1239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design, synthesis and antitumor activity of thiadiazole derivatives as novel ALK kinase inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Yiwen","family":"Huo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinjiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanna","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"11259_CR1","doi-asserted-by":"publisher","first-page":"116108","DOI":"10.1016\/j.bmc.2021.116108","volume":"37","author":"Z Li","year":"2021","unstructured":"Li Z, Guo M, Cao M, Zhao T, Li M, Zhai X (2021) Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. Bioorgan Med Chem 37:116108","journal-title":"Bioorgan Med Chem"},{"key":"11259_CR2","first-page":"900","volume":"23","author":"V Asati","year":"2023","unstructured":"Asati V, Ayaz MS, Bhupal R, Sharma P, Sahu A, Singh P, Gupta GD (2023) Recent updates on structural aspects of ALK inhibitors as an anticancer agent, anti-cancer agents. Med Chem 23:900\u2013921","journal-title":"Med Chem"},{"key":"11259_CR3","first-page":"118712","volume":"1867","author":"W Gou","year":"2020","unstructured":"Gou W, Li Z, Xu X, Shen J, Guo M, Zhou X, Zhang X, Wu Y, Zhai X, Zuo D (2020) ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation. BBA-Mol Cell Res 1867:118712","journal-title":"BBA-Mol Cell Res"},{"key":"11259_CR4","doi-asserted-by":"publisher","first-page":"117071","DOI":"10.1016\/j.bmc.2022.117071","volume":"75","author":"J Ren","year":"2022","unstructured":"Ren J, Gao Y, Shi W, Xu S, Wang Q, Zhao D, Kong L, Song W, Wang X, Zhang Y, He X, Wang Y, Tong S, Lu P, Li Y, Xu H, Zhang Y (2022) Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy. Bioorgan Med Chem 75:117071","journal-title":"Bioorgan Med Chem"},{"key":"11259_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","volume":"31","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31:1105\u20131111","journal-title":"J Clin Oncol"},{"key":"11259_CR6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, MacNeill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu T-L, Polakiewicz RD, Rush J, Comb MJ (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190\u20131203","journal-title":"Cell"},{"key":"11259_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"key":"11259_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","volume":"158","author":"SS Zhang","year":"2021","unstructured":"Zhang SS, Nagasaka M, Zhu VW, Ou S-HI (2021) Going beneath the tip of the iceberg, Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer 158:126\u2013136","journal-title":"Lung Cancer"},{"issue":"2","key":"11259_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3892\/ol.2022.13397","volume":"24","author":"LY Lei","year":"2022","unstructured":"Lei LY, Shi X et al (2022) EML4-ALK fusion gene in non-small cell lung cancer. Oncol Lett 24(2):277","journal-title":"Oncol Lett"},{"key":"11259_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou S-HI, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang Y-J, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004\u20131012","journal-title":"Lancet Oncol"},{"key":"11259_CR11","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-11-1648","volume":"17","author":"JM Heuckmann","year":"2011","unstructured":"Heuckmann JM, H\u00f6lzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Gr\u00fctter C, Rauh D, Pao W, Thomas RK (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17:7394\u20137401","journal-title":"Clin Cancer Res"},{"key":"11259_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s43018-022-00390-1","volume":"3","author":"L He","year":"2022","unstructured":"He L, Dar AC (2022) Targeting drug-resistant mutations in ALK. Nat Cancer 3:659\u2013661","journal-title":"Nat Cancer"},{"key":"11259_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fonc.2018.00557","volume":"8","author":"M Khan","year":"2019","unstructured":"Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y (2019) ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol 8:557","journal-title":"Front Oncol"},{"key":"11259_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11523-016-0460-7","volume":"11","author":"ED Deeks","year":"2016","unstructured":"Deeks ED (2016) Ceritinib: a review in ALK-positive advanced NSCLC. Target Oncolo 11:693\u2013700","journal-title":"Target Oncolo"},{"key":"11259_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY (2019) Lorlatinib: first global approval. Drugs 79:93\u201398","journal-title":"Drugs"},{"key":"11259_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11101-009-9122-z","volume":"8","author":"C Scherer","year":"2009","unstructured":"Scherer C, Jacob C, Dicato M, Diederich M (2009) Potential role of organic sulfur compounds from Allium species in cancer prevention and therapy. Phytochem Rev 8:349\u2013368","journal-title":"Phytochem Rev"},{"key":"11259_CR17","doi-asserted-by":"publisher","first-page":"110262","DOI":"10.1016\/j.cbi.2022.110262","volume":"369","author":"S Cai","year":"2023","unstructured":"Cai S, Ding Z, Liu X, Zeng J (2023) Trabectedin induces ferroptosis via regulation of HIF-1\u03b1\/IRP1\/TFR1 and Keap1\/Nrf2\/GPX4 axis in non-small cell lung cancer cells. Chem Biol Interact 369:110262","journal-title":"Chem Biol Interact"},{"key":"11259_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Alpelisib: first global approval. Drugs 79:1249\u20131253","journal-title":"Drugs"},{"key":"11259_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12032-024-02401-w","volume":"41","author":"T Jamison","year":"2024","unstructured":"Jamison T, Haque E, Muhsen IN, Samarkandi H, Fakih RE, Aljurf M (2024) Revisiting intrathecal thiotepa: efficacy and safety in secondary CNS malignancies. Med Oncol 41:177","journal-title":"Med Oncol"},{"key":"11259_CR20","first-page":"681","volume":"33","author":"GVR Sharma","year":"2022","unstructured":"Sharma GVR, Madhavi B (2022) Recent developments on novel heterocyclic compounds thiadiazoles and heterocyclic compounds for COVID-19 targets in drug discovery. J Pharm Res Int 33:681\u2013697","journal-title":"J Pharm Res Int"},{"key":"11259_CR21","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1021\/jm500374c","volume":"57","author":"R Shang","year":"2014","unstructured":"Shang R, Pu X, Xu X, Xin Z, Zhang C, Guo W, Liu Y, Liang J (2014) Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors. J Med Chem 57:5664\u20135678","journal-title":"J Med Chem"},{"key":"11259_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2174\/1871520623666221221143918","volume":"23","author":"V Sharma","year":"2023","unstructured":"Sharma V, Kaur B, Singh G, Singh I (2023) Sulphur containing heterocyclic compounds as anticancer agents. Anticancer Agents Med Chem 23:869\u2013881","journal-title":"Anticancer Agents Med Chem"},{"key":"11259_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41061-018-0184-5","volume":"376","author":"KA Scott","year":"2018","unstructured":"Scott KA, Njardarson JT (2018) Analysis of US FDA-approved drugs containing sulfur atoms. Top Curr Chem 376:5","journal-title":"Top Curr Chem"},{"key":"11259_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ejmech.2019.04.012","volume":"173","author":"I Celik","year":"2019","unstructured":"Celik I, Ayhan-Kilcigil G, Guven B, Kara Z, Gurkan-Alp AS, Karayel A, Onay-Besikci A (2019) Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors. Eur J Med Chem 173:240\u2013249","journal-title":"Eur J Med Chem"},{"key":"11259_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2018.03.026","volume":"118","author":"V Raj","year":"2019","unstructured":"Raj V, Bhadauria AS, Singh AK, Kumar U, Rai A, Keshari AK, Kumar P, Kumar D, Maity B, Nath S, Prakash A, Ansari KM, Jat JL, Saha S (2019) Novel 1,3,4-thiadiazoles inhibit colorectal cancer via blockade of IL-6\/COX-2 mediated JAK2\/STAT3 signals as evidenced through data-based mathematical modeling. Cytokine 118:144\u2013159","journal-title":"Cytokine"},{"key":"11259_CR26","doi-asserted-by":"publisher","first-page":"17557","DOI":"10.1039\/D4RA01556H","volume":"14","author":"H Yao","year":"2024","unstructured":"Yao H, Ren Y, Wu F, Liu J, Cao L, Yan M, Li X (2024) The synthesis and evaluation of novel ALK inhibitors containing the sulfoxide structure. RSC Adv 14:17557\u201317570","journal-title":"RSC Adv"},{"key":"11259_CR27","doi-asserted-by":"publisher","first-page":"114626","DOI":"10.1016\/j.ejmech.2022.114626","volume":"241","author":"J Yang","year":"2022","unstructured":"Yang J, Ma D, Liu SY, Tan ZH, Guo M, Cao Z, Zhang JH, Zhai X (2022) Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors. Eur J Med Chem 241:114626","journal-title":"Eur J Med Chem"},{"key":"11259_CR28","doi-asserted-by":"publisher","first-page":"113259","DOI":"10.1016\/j.ejmech.2021.113259","volume":"214","author":"M Guo","year":"2021","unstructured":"Guo M, Zuo DY, Zhao TM, Li XY, Cao JS, Qiu YX, Wei SF, Zhai X (2021) Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK\/ROS1 dual inhibitors with anti-mutation effects. Eur J Med Chem 214:113259","journal-title":"Eur J Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11259-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11259-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11259-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:56:39Z","timestamp":1771775799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11259-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11259"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11259-7","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}